[go: up one dir, main page]

AR076634A1 - Composiciones y metodo para tratar desordenes del sistema nervioso central - Google Patents

Composiciones y metodo para tratar desordenes del sistema nervioso central

Info

Publication number
AR076634A1
AR076634A1 ARP090104483A ARP090104483A AR076634A1 AR 076634 A1 AR076634 A1 AR 076634A1 AR P090104483 A ARP090104483 A AR P090104483A AR P090104483 A ARP090104483 A AR P090104483A AR 076634 A1 AR076634 A1 AR 076634A1
Authority
AR
Argentina
Prior art keywords
liposomal
administration vehicle
pegylated
therapeutic composition
vehicle
Prior art date
Application number
ARP090104483A
Other languages
English (en)
Inventor
Thomas Redelmeier
Original Assignee
Medgenesis Therapeutix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medgenesis Therapeutix Inc filed Critical Medgenesis Therapeutix Inc
Publication of AR076634A1 publication Critical patent/AR076634A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
    • A61K49/0076—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form dispersion, suspension, e.g. particles in a liquid, colloid, emulsion
    • A61K49/0084—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form dispersion, suspension, e.g. particles in a liquid, colloid, emulsion liposome, i.e. bilayered vesicular structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0023—Di-or triarylmethane dye
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/0021—Catheters; Hollow probes characterised by the form of the tubing
    • A61M2025/0042—Microcatheters, cannula or the like having outside diameters around 1 mm or less
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/0067—Catheters; Hollow probes characterised by the distal end, e.g. tips
    • A61M25/0068—Static characteristics of the catheter tip, e.g. shape, atraumatic tip, curved tip or tip structure
    • A61M25/007—Side holes, e.g. their profiles or arrangements; Provisions to keep side holes unblocked

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Reivindicacion 1: Un vehículo de administracion liposomal no pegilado mejorado para la liberacion de agentes farmacéuticos por administracion mejorada por conveccion en el sistema nervioso central caracterizado por comprender un agente terapéutico o diagnostico encapsulado en una formulacion liposomal que comprende al menos un fosfolípido neutro saturado y al menos un fosfolípido anionico saturado. Reivindicacion 3: El vehículo de administracion Iiposomal no pegilado de la reivindicacion 1, caracterizado porque además comprende un esterol. Reivindicacion 4: El vehículo de administracion liposomal no pegilado de la reivindicacion 3, caracterizado porque dicha formulacion liposomal comprende esencialmente DSPC, DSPG y CHOL. Reivindicacion 6: Una composicion terapéutica que comprende el vehículo de administracion liposomal no pegilado de cualquiera de las reivindicaciones 1-5, caracterizada porque dicho vehículo de administracion liposomal encapsula un inhibidor de topoisomerasa. Reivindicacion 7: La composicion terapéutica de la reivindicacion 6, caracterizada porque dicho inhibidor de topoisomerasa es topotecan. Reivindicacion 9: Una composicion terapéutica que comprende el vehículo de administracion liposomal no pegilado de las reivindicaciones 1-5, caracterizada porque dicho vehículo de administracion liposomal encapsula una toxina. Reivindicacion 11: La composicion terapéutica de la reivindicacion 10, caracterizada porque dicha toxina proteica es una conotoxina. Reivindicacion 19: Una composicion diagnostica que comprende el vehículo de administracion liposomal no pegilado segun cualquiera de las reivindicaciones 1-5, caracterizada porque dicho vehículo de administracion liposomal encapsula un Imán de MRI. Reivindicacion 20: La composicion diagnostica de la reivindicacion 19, caracterizada porque el imán de MRI se selecciona de un grupo que consiste de gadodiamida y rodamina.
ARP090104483A 2008-11-21 2009-11-20 Composiciones y metodo para tratar desordenes del sistema nervioso central AR076634A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11707608P 2008-11-21 2008-11-21

Publications (1)

Publication Number Publication Date
AR076634A1 true AR076634A1 (es) 2011-06-29

Family

ID=42197794

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090104483A AR076634A1 (es) 2008-11-21 2009-11-20 Composiciones y metodo para tratar desordenes del sistema nervioso central

Country Status (9)

Country Link
US (1) US9295735B2 (es)
EP (1) EP2370058B1 (es)
JP (1) JP5795537B2 (es)
CN (1) CN102256596B (es)
AR (1) AR076634A1 (es)
AU (1) AU2009317837B2 (es)
BR (1) BRPI0922100A2 (es)
CA (1) CA2743959C (es)
WO (1) WO2010057317A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201204263D0 (en) * 2012-03-12 2012-04-25 Renishaw Plc Giloma treatment
US20150258085A1 (en) * 2012-10-19 2015-09-17 The Regents Of The University Of California Treating Tumors of the Central Nervous System
US9993427B2 (en) 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture
GB2534315B (en) * 2013-10-02 2020-08-05 Univ Leland Stanford Junior WNT compositions and methods for purification
HK1246815A1 (zh) 2015-01-16 2018-09-14 Voyager Therapeutics, Inc. 针对多核苷酸的中枢神经系统
US20170049701A1 (en) * 2015-08-05 2017-02-23 Steven M. Kushner Clustoidal multilamellar soy lecithin phospholipid structures for transdermal, transmucosal, or oral delivery, improved intestinal absorption, and improved bioavailability of nutrients
EP3444004B1 (en) 2016-04-15 2020-12-02 FUJIFILM Corporation Microneedle array
CN116763734A (zh) * 2017-03-31 2023-09-19 富士胶片株式会社 脂质体组合物的制造方法
US11344497B1 (en) 2017-12-08 2022-05-31 Quicksilver Scientific, Inc. Mitochondrial performance enhancement nanoemulsion
US10722465B1 (en) * 2017-12-08 2020-07-28 Quicksilber Scientific, Inc. Transparent colloidal vitamin supplement
US20210207167A1 (en) 2018-05-16 2021-07-08 Voyager Therapeutics, Inc. Aav serotypes for brain specific payload delivery
FI3811931T3 (fi) 2018-06-20 2024-09-12 Fujifilm Corp Liposomikoostumukseen kapseloidun lääkkeen ja immuunitarkistuspisteinhibiittorin sisältävä yhdistelmälääkitys
TWI837189B (zh) 2018-10-01 2024-04-01 日商富士軟片股份有限公司 包含內含藥物之脂質體組成物及鉑製劑之組合醫藥
US11291702B1 (en) 2019-04-15 2022-04-05 Quicksilver Scientific, Inc. Liver activation nanoemulsion, solid binding composition, and toxin excretion enhancement method
US20240024220A1 (en) * 2019-05-11 2024-01-25 Youngsuk Yi Neurotoxin compositions and methods
CN114469863B (zh) * 2021-11-26 2023-09-26 南方医科大学南方医院 甾醇脂质体作为牙髓和牙本质药物传递系统的应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5077056A (en) 1984-08-08 1991-12-31 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US5171578A (en) 1985-06-26 1992-12-15 The Liposome Company, Inc. Composition for targeting, storing and loading of liposomes
US4925664A (en) * 1986-10-20 1990-05-15 University Of Utah Spider toxins and methods for their use as blockers of calcium channels and amino acid receptor function
IL91664A (en) 1988-09-28 1993-05-13 Yissum Res Dev Co Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release
RU2207808C2 (ru) * 1998-04-09 2003-07-10 Амершем Хелт АС Применение контрастных агентов в форме частиц в диагностической визуализации для изучения физиологических параметров
GB0111279D0 (en) * 2001-05-10 2001-06-27 Nycomed Imaging As Radiolabelled liposomes
ES2387886T3 (es) * 2001-11-13 2012-10-03 Celator Pharmaceuticals, Inc. Composiciones que transportan lípidos con una mejor estabilidad sanguínea
CN1391891A (zh) * 2002-04-22 2003-01-22 江苏佩沃特生物基因工程有限公司 紫杉醇隐形脂质体
EP1608337A2 (en) * 2003-04-02 2005-12-28 Celator Technologies Inc. Combination compositions of camptothecins and fluoropyrimidines
WO2005079185A2 (en) 2003-09-02 2005-09-01 Board Of Regents, The University Of Texas System Neutral liposome-encapsulated compounds and methods of making and using thereof
US8658203B2 (en) * 2004-05-03 2014-02-25 Merrimack Pharmaceuticals, Inc. Liposomes useful for drug delivery to the brain
CN100356919C (zh) * 2004-05-31 2007-12-26 上海医药工业研究院 羟基喜树碱脂质体及其制备方法
WO2006127962A2 (en) 2005-05-25 2006-11-30 Becton, Dickinson And Comapny Particulate formulations for intradermal delivery of biologically active agents
EP2279726A3 (en) * 2005-05-26 2012-06-20 Biorest Ltd. Compositions and methods using same for delivering agents into a target organ protected by a blood barrier
CN1823733A (zh) * 2006-01-06 2006-08-30 中国药科大学 一种含喜树碱类药物的自组装前体脂质体及其制备方法
WO2007106549A2 (en) * 2006-03-15 2007-09-20 Alza Corporation Method for treating brain cancer
JP2009535360A (ja) 2006-04-26 2009-10-01 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 高分子量神経治療薬の対流増加送達のための組成物および方法
US8790317B2 (en) * 2007-02-13 2014-07-29 Cornell University Convection enhanced delivery apparatus, method, and application
US20090209937A1 (en) * 2007-08-11 2009-08-20 Argenis Llc Apparatus and Methods for Treating Epilepsy Using Convection-Enhanced Delivery

Also Published As

Publication number Publication date
US9295735B2 (en) 2016-03-29
WO2010057317A1 (en) 2010-05-27
CA2743959C (en) 2017-09-26
EP2370058A4 (en) 2013-11-20
JP5795537B2 (ja) 2015-10-14
BRPI0922100A2 (pt) 2016-02-10
US20110274625A1 (en) 2011-11-10
EP2370058A1 (en) 2011-10-05
JP2012509284A (ja) 2012-04-19
EP2370058B1 (en) 2017-10-18
AU2009317837B2 (en) 2016-02-25
AU2009317837A1 (en) 2011-06-30
CN102256596B (zh) 2014-10-22
CA2743959A1 (en) 2010-05-27
CN102256596A (zh) 2011-11-23

Similar Documents

Publication Publication Date Title
AR076634A1 (es) Composiciones y metodo para tratar desordenes del sistema nervioso central
Ajmo Jr et al. Sigma receptor activation reduces infarct size at 24 hours after permanent middle cerebral artery occlusion in rats
JP6596475B2 (ja) ナノ粒子組成物、その製剤およびその使用
MX395136B (es) Composiciones farmaceuticas y metodos de administracion relacionados.
EP3964200A1 (en) Compositions and methods for delivery of therapeutic agents
EP4218722A3 (en) Biodegradable lipids for the delivery of active agents
MA26834A1 (fr) Nouveau medicament contraceptif et son mode de preparation
Chu et al. Biomaterials-based anti-inflammatory treatment strategies for Alzheimer’s disease
CO7101246A2 (es) Compuesto de carbamato y preparación y uso de los mismos
EP2246049A3 (en) Pharmaceutical composition and dosage forms for administration of hydrophobic drugs
AR095962A1 (es) Nanopartículas, compuestas de esterol y saponina de quillaja saponaria molina, proceso para preparación y uso de las mismas como portadores para moléculas anfipáticas o hidrófobas en el campo de la medicina incluyendo tratamiento de cáncer y compuestos relacionados con alimentos
DE60138468D1 (de) Cyanophenoxy-carbonsäuren und zusammensetzungen für die freisetzung aktiver substanzen
RU2011103136A (ru) Фармацевтическая композиция на основе тонкоизмельченного прогестерона и ее применения
BR112013025517A2 (pt) uso de 2,3-diidroimidazo[1,2-c]quinazolinas substituídas
US8703179B2 (en) Mucosal formulation
Zhang et al. The effect of pyrroloquinoline quinone on apoptosis and autopha gy in traumatic brain injury
BR0109672A (pt) Uso de zd6126 ou de um seu sal farmaceuticamente aceitável e um de: um agente antitumoral de plantina e um taxano, composição farmacêutica, produto de combinação, kit, e, método para a produção de um efeito de danificação vascular em um animal de sangue quente
Haghighi et al. Preparation, characterization and evaluation of Ginkgo biloba solid lipid nanoparticles
Zou et al. Effectiveness of minocycline in acute white matter injury after intracerebral hemorrhage
PH12013500357A1 (en) A water-in-oil type emulsion for treating a disease of the eye
BRPI0409796A (pt) uso de dipiridamol ou mopidamol para tratamento e prevenção de doenças tromboembolìticas e distúrbios provocados pela formação excessiva de trombina e/ou pela expressão elevada de receptores de trombina
GT200200115A (es) Formulacion farmaceutica de sabor enmascarado y procedimiento para su preparacion
CN117323438A (zh) 四面体框架核酸-姜黄素复合物在制备预防和/或治疗糖尿病性骨质疏松的药物中的用途
Dutta A study from structural insight to the antiamyloidogenic and antioxidant activities of flavonoids: Scaffold for future therapeutics of Alzheimer’s disease
BRPI0506630A (pt) composição de liberação controlada e método para administrar um medicamento aquoso transmucosal de liberação controlada

Legal Events

Date Code Title Description
FB Suspension of granting procedure